Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ZNTL, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Azenosertib | Ovarian Cancer | Phase 3 · NCT07546500 | Recruiting |
| Investigator's choice of chemotherapy | Ovarian Cancer | Phase 3 · NCT07546500 | Recruiting |
| Gemcitabine Hydrochloride | Advanced Pancreatic Adenocarcinoma | Phase 2 · NCT06015659 | Terminated |
| Asaretoclax | Amyloidosis | Phase 1/2 · NCT05199337 | Completed |
| ZN-d5 ZN-c3 | Acute Myeloid Leukemia (AML) | Phase 1/2 · NCT05682170 | Terminated |
| Pegylated Liposomal Doxorubicin Hydrochloride | Solid Tumor | Phase 1 · NCT04516447 | Recruiting |
Also used in these trials (approved or third-party drugs, not ZNTL's own candidates): Niraparib, Bevacizumab, Carboplatin, Cetuximab, Encorafenib, Paclitaxel, Pembrolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ZNTL holds $228.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $35M/quarter from operations, an estimated runway of 19.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 62 · High
The Company determined that there are no conditions or events that raise substantial doubt about its ability to continue as a going concern within one year after the date that the interim unaudited condensed consolidated financial statements for the quarter ended September 30, 2026 are issued.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ZNTL files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| WALTERS GROUP 10% owner |
Insider | 17,844,973 | 18.16% | 2026-08-14 |
| Walters William T | 5%+ holder (13G) | 17,844,973 | 18.16% | 2026-08-14 |
| Matrix Capital Management Company, LP 10% owner |
Insider | 6,459,973 | 6.57% | 2025-12-15 |
| Andrew J. Schwab | 5%+ holder (13G) | 4,838,571 | 4.92% | 2025-12-18 |
| Squadron Master Fund LP | 5%+ holder (13G) | 3,676,900 | 3.74% | 2026-02-24 |
| Andrea Paul Chief Legal Officer · +124,714 options |
Insider | 1,070,784 | 1.09% | 2025-02-03 |
| Mark Lackner Chief Scientific Officer · +124,714 options |
Insider | 512,856 | 0.52% | 2025-02-03 |
| Scott Dunseth Myers Director |
Insider | 395,895 | 0.40% | 2026-06-16 |
| David Michael Johnson Director |
Insider | 307,521 | 0.31% | 2026-06-16 |
| Jan Skvarka Director |
Insider | 264,254 | 0.27% | 2026-06-16 |
| Luke Nathaniel Walker Director |
Insider | 201,384 | 0.20% | 2026-06-16 |
| Enoch Kariuki Director |
Insider | 194,465 | 0.20% | 2026-06-16 |
Share count 98,265,863 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ZNTL and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →